A newly published systematic review and meta-analysis in Frontiers in Nutrition evaluated 26 randomised controlled trials involving 668 healthy participants, providing one of the most comprehensive assessments on the effects of Rhodiola rosea supplementation on physical performance and recovery outcomes.
The analysis demonstrated that Rhodiola rosea significantly improves key endurance metrics, including VO2max, time to exhaustion (TTE), and time trial performance (TTP). In parallel, supplementation enhanced physiological resilience by increasing antioxidant capacity (superoxide dismutase, SOD, total antioxidant capacity, TAC) and reducing markers of oxidative stress (lowering malondialdehyde levels, MDA) and muscle damage (creatine kinase, CK), as well as improving metabolic efficiency through reduced lactate levels.
“Mechanistically, these benefits are attributed to Rhodiola’s bioactive compounds, particularly salidroside, which support mitochondrial function, energy metabolism, and cellular protection against exercise-induced stress,” says Dr. Stacey Smith, Senior Medical Affairs Liaison with Gnosis by Lesaffre, noting that not only were the majority of the 26 randomised controlled trials (RCTs) of good quality, but they spanned across multiple geographies (Asia, Europe, US) and populations to enhance generalisability. “Further, demographics were men, women and mixed groups: age from 11 to 45 years.”
Pure Salidroside as the Effective Choice
No adverse effects were reported across the studies, showing that Rhodiola rosea was well-tolerated. Subgroup analyses suggest that higher daily intake levels (>600 mg/day) may drive greater improvements in aerobic capacity, reinforcing dose-dependent efficacy. However, Dr. Smith notes an interesting observation with the inclusion of the LANDKIND Pure Salidroside trial.
“This meta-analysis reinforces that Rhodiola’s benefits are dose-dependent, with the strongest effects observed at ≥600 mg/day of extract. Given that salidroside is a key bioactive component of Rhodiola, there is support in the importance of delivering this compound effectively,” she explains. “It is noteworthy that, as a key bioactive, LANDKIND Pure Salidroside is effective at dosages far below what is required for the same effect of Rhodiola rosea – 60mg/day vs. the mean range of 400-700 mg/day.
“Targeted salidroside delivery with LANDKIND Pure Salidroside represents a rational next step to optimise efficacy, and potentially enable a more precise, lower-dose ingredient for formulations compared to traditional whole extracts,” Dr. Smith concludes.
As the nutraceutical industry evolves toward greater precision, transparency, and sustainability, the future of adaptogens will be shaped by scientifically validated, highly controlled bioactives. LANDKIND Pure Salidroside embodies this next generation—where purity, clinical evidence, and responsible production converge to unlock the full potential of Rhodiola’s benefits. By delivering a targeted, consistent, and sustainable source of salidroside, LANDKIND sets a new benchmark for adaptogenic innovation, empowering brands to move beyond conventional extracts and embrace a more precise, effective standard for performance, resilience, and well-being.
